LMAT Stock Analysis: LeMaitre Vascular | NASDAQ
Medical Instruments & Supplies | NASDAQ, USA | Market Cap: 1.791m USD | 12M Return: -11.6% | US5255582018 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 22.1M
EPS Trend: 98.6%
Qual. Beats: 0
Rev. Trend: 99.9%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
LeMaitre Vascular, Inc. (NASDAQ: LMAT) is a U.S.-based medical device manufacturer specializing in surgical implants and instruments used in vascular surgery, with operations spanning the Americas, Europe, the Middle East, Africa, and Asia Pacific. The companys product portfolio is diverse and clinically focused, spanning catheters (embolectomy, thrombectomy, occlusion, and perfusion), biologic grafts and patches, vascular grafts, carotid shunts, valvulotomes, and closure systems, along with cryopreserved human tissue services. It markets its products through a combination of direct sales representatives and third-party distributors, and is headquartered in Burlington, Massachusetts, having been incorporated in 1983 (originally as Vascutech, Inc., before adopting its current name in April 2001).
The companys offerings reflect the fragmented nature of the vascular surgery device market, where single-vendor solutions are rare and product breadth across multiple clinical applications-dialysis access, peripheral bypass, varicose vein treatment, and cardiac repair-provides competitive insulation. Its inclusion of biologic and cryopreserved allograft products is notable, as these tissue-based offerings typically require specialized storage, donor screening, and regulatory compliance that differ from conventional manufactured implants, adding operational complexity but also differentiation within the broader Health Care Equipment sub-industry.
- XenoSure biologic patch sales accelerate high-margin growth
- European FX headwinds pressure reported revenue
- Tuck-in M&A expands vascular surgery product portfolio
| Net Income: 63.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA 0.43 > 1.0 |
| NWC/Revenue: 174.8% < 20% (prev 173.8%; Δ 0.97% < -1%) |
| CFO/TA 0.12 > 3% & CFO 76.2m > Net Income 63.3m |
| Net Debt (-181.3m) to EBITDA (91.6m): -1.98 < 3 |
| Current Ratio: 14.60 > 1.5 & < 3 |
| Outstanding Shares: last quarter (23.1m) vs 12m ago -5.42% < -2% |
| Gross Margin: 72.04% > 18% (prev 70.97%; Δ 1.08% > 0.5%) |
| Asset Turnover: 42.96% > 50% (prev 40.27%; Δ 2.68% > 0%) |
| Interest Coverage Ratio: 15.54 > 6 (EBIT TTM 80.9m / Interest Expense TTM 5.20m) |
| A: 0.72 (Total Current Assets 505.5m - Total Current Liabilities 34.6m) / Total Assets 656.0m |
| B: 0.33 (Retained Earnings 215.3m / Total Assets 656.0m) |
| C: 0.13 (EBIT TTM 80.9m / Avg Total Assets 627.1m) |
| D: 1.93 (Book Value of Equity 432.1m / Total Liabilities 223.9m) |
| Altman-Z'' = 8.67 = AAA |
| DSRI: 0.99 (Receivables 35.9m/32.4m, Revenue 269.4m/240.9m) |
| GMI: 0.99 (GM 70.97% / 72.04%) |
| AQI: 0.89 (AQ_t 0.15 / AQ_t-1 0.17) |
| SGI: 1.12 (Revenue 269.4m / 240.9m) |
| TATA: -0.02 (NI 63.3m - CFO 76.2m) / TA 656.0m) |
| Beneish M = -3.03 (Cap -4..+1) = AA |
As of November 18, 2026, the stock is trading at USD 76.10 with a total of 190,505 shares traded. Over the past week, the price has changed by -3.70%, over one month by -7.54%, over three months by -7.49% and over the past year by -11.63%.
Current recommended Stop Loss: 72.60 (which is 4.6% or 1.3 ATR below the current price).
LeMaitre Vascular has received a consensus analysts rating of 3.75. Therefore, it is recommended to hold LMAT.
- StrongBuy: 2
- Buy: 2
- Hold: 4
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 99.3 | 30.5% |
P/E Trailing = 28.4691
P/E Forward = 24.9377
P/S = 6.6505
P/B = 4.1411
P/EG = 2.0756
Revenue TTM = 269.4m USD
EBIT TTM = 80.9m USD
EBITDA TTM = 91.6m USD
Long Term Debt = 169.3m USD (from longTermDebt, last quarter)
Short Term Debt = 3.19m USD (from shortTermDebt, last quarter)
Debt = 208.4m USD (from shortLongTermDebtTotal, last quarter) + Leases 19.5m
Net Debt = -181.3m USD (calculated: Debt 208.4m - CCE 389.7m)
Enterprise Value = 1.61b USD (1.79b + Debt 208.4m - CCE 389.7m)
Interest Coverage Ratio = 15.54 (Ebit TTM 80.9m / Interest Expense TTM 5.20m)
EV/FCF = 22.04x (Enterprise Value 1.61b / FCF TTM 73.1m)
FCF Yield = 4.54% (FCF TTM 73.1m / Enterprise Value 1.61b)
FCF Margin = 27.12% (FCF TTM 73.1m / Revenue TTM 269.4m)
Net Margin = 23.51% (Net Income TTM 63.3m / Revenue TTM 269.4m)
Gross Margin = 72.04% ((Revenue TTM 269.4m - Cost of Revenue TTM 75.3m) / Revenue TTM)
Gross Margin QoQ = 71.66% (prev 72.13%)
Tobins Q-Ratio = 2.45 (Enterprise Value 1.61b / Total Assets 656.0m)
Interest Expense / Debt = 2.50% (Interest Expense 5.20m / Debt 208.4m)
Taxrate = 22.61% (18.5m / 81.8m)
NOPAT = 62.6m (EBIT 80.9m * (1 - 22.61%))
Current Ratio = 13.04 (Total Current Assets 505.5m / Total Current Liabilities 38.8m)
Debt / Equity = 0.48 (Debt 208.4m / totalStockholderEquity, last quarter 432.1m)
Debt / EBITDA = -1.98 (Net Debt -181.3m / EBITDA 91.6m)
Debt / FCF = -2.48 (Net Debt -181.3m / FCF TTM 73.1m)
Total Stockholder Equity = 413.2m (last 4 quarters mean from totalStockholderEquity)
RoA = 10.10% (Net Income 63.3m / Total Assets 656.0m)
RoE = 15.33% (Net Income TTM 63.3m / Total Stockholder Equity 413.2m)
RoCE = 13.88% (EBIT 80.9m / Capital Employed (Equity 413.2m + L.T.Debt 169.3m))
RoIC = 10.24% (NOPAT 62.6m / Invested Capital 611.1m)
WACC = 5.22% (E(1.79b)/V(2.00b) * Re(5.60%) + D(208.4m)/V(2.00b) * Rd(2.50%) * (1-Tc(0.23)))
Discount Rate = 5.60% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 48.20 | Cagr: 0.67%
[DCF] Terminal Value 77.83% ; FCFF base≈69.5m ; Y1≈79.0m ; Y5≈113.9m
[DCF] Fair Price = 82.98 (EV 1.72b - Net Debt -181.3m = Equity 1.90b / Shares 22.9m; r=8.35% [WACC [floored]]; 5y FCF grow 14.07% → 2.50% )
EPS Correlation: 98.59 | EPS CAGR: 30.49% | SUE: -0.53 | # QB: 0
Revenue Correlation: 99.92 | Revenue CAGR: 12.99% | SUE: 0.45 | # QB: 0
EPS current Quarter (2027-03-31): EPS=0.76 | Chg30d=-0.85% | Revisions=-25% | Analysts=5
EPS current Year (2026-12-31): EPS=2.81 | Chg30d=-2.46% | Revisions=-57% | GrowthEPS=+11.4% | GrowthRev=+10.6%
EPS next Year (2027-12-31): EPS=3.15 | Chg30d=-0.91% | Revisions=-40% | GrowthEPS=+12.2% | GrowthRev=+9.9%
[Analyst] Revisions Ratio: -70% (up=0, down=7)